Successful Treatment of Pembrolizumab-associated Myositis-myocarditis-myasthenia Gravis Overlap Syndrome with Gastrointestinal Pseudo-obstruction Using Zilucoplan: A Case Report
Myositis-myocarditis-myasthenia gravis (MMM) overlap syndrome is a rare, potentially fatal complication of immune checkpoint inhibitor (ICI) therapy. We report a 74-year-old man with pre-existing thymoma and anti-acetylcholine receptor antibody positivity who developed pembrolizumab-induced MMM complicated by gastrointestinal pseudo-obstruction (GIPO). Despite the administration of corticosteroids and intravenous immunoglobulin, ocular symptoms persisted, and bowel dysmotility progressed. We initiated zilucoplan, a complement C5 inhibitor. Within days, diplopia and dysphagia resolved, and GIPO markedly improved on radiography, enabling oral intake. To our knowledge, this is the first case of pembrolizumab-induced MMM treated with zilucoplan and the first ICI-mediated GIPO managed with a complement inhibitor.
Authors
- Taro Bannai (ORCID: https://orcid.org/0000-0002-1664-1932)
- Meiko Hashimoto Maeda (ORCID: https://orcid.org/0000-0002-3725-3488)
- Tomonari Seki (ORCID: https://orcid.org/0009-0004-6154-5562)
- Hiroki Komatsu
- Yusuke Sugiyama
- Yuki Nagasako (ORCID: https://orcid.org/0009-0002-4834-9394)
- Shogo Komaki
- Akatsuki Kubota (ORCID: https://orcid.org/0000-0001-5623-3602)
- Yasushi Shiio
- Minako Yamada (ORCID: https://orcid.org/0000-0002-4970-0994)
- Ken Wako
Institutions
- Tokyo Teishin Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Internal Medicine
- Published
- 2026-11-19
- DOI
- https://doi.org/10.2169/internalmedicine.7985-26
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00